Use of antisense oligonucleotides against CPLA2 in the treatment of cancer
AssigneesMor Research Applications Ltd., Ben-Gurion University of the Negev Research and Development Authority
InventorRachel Levy
Life of this patent
Estimating the term…
Abstract
Inhibitors of cPLA2α expression are used in the preparation of pharmaceutical compositions for the inhibition of cancer cell proliferation and for the treatment of cancer; the inhibitors are selected from cPLA2α-specific ribozymes, RNA sequences usable for RNA-interference of the cPLA2α gene, and antisense oligonucleotides directed against cPLA2α.
Claims3
A method for treating colon cancer in a mammalian human subject in need thereof which comprises administering to the subject a pharmaceutical composition having an active agent which consists of an inhibitor of cPLA2α expression wherein said inhibitor is selected from the group consisting of a cPLA2α-specific ribozyme, a double stranded nucleotide sequence used for RNA interference of the cPLA2α gene, and an antisense oligonucleotide directed against cPLA2α.
Dependencies are inferred from the claim text.